Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-39758979/ MTX · 1 trial · 1 indication
To assess the effect of multiple doses of JNJ-39758979 on blood levels of methotrexate
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JNJ-39758979 / MTX | DRUG | Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily. |
Inclusion Criteria: * Diagnosis of Rheumatoid Arthritis Functional Class I-III according to the American College of Rheumatology criteria for at least 3 months prior to Screening * Have been treated with and tolerated oral methotrexate (taken by mouth) for a minimum of 3 months prior to screening, ...
Top 20 of 28 competitors
JNJ-39758979 is an investigational small molecule being studied for the treatment of asthma and rheumatoid arthritis. It is being developed by Johnson & Johnson (JNJ) and has been evaluated in clinical trials for these conditions.
JNJ-39758979 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company has sponsored clinical trials of the drug in asthma and rheumatoid arthritis.
JNJ-39758979 is an investigational drug that has completed clinical trials. One trial was a Phase 2 study in asthma, and another was a Phase 1 study in rheumatoid arthritis. It is not approved and remains in clinical development.
JNJ-39758979 has been studied in two completed trials. NCT00946569 was a Phase 2 study in adults with persistent asthma, enrolling 116 participants in the United States, Canada, India, and Romania. NCT01442545 was a Phase 1 study in rheumatoid arthritis participants, enrolling 21 participants in the United States and Germany.
JNJ-39758979 is not the same as MTX, which is methotrexate. In a clinical trial, JNJ-39758979 was studied to investigate how it may affect the plasma levels of methotrexate in rheumatoid arthritis participants, indicating the two are distinct drugs.